You are here: Industry Insights > Janssen

News List

Updates for the Janssen and AstraZeneca Vaccines Cross-contamination Lin Zhang
July 13, 2021
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes COVID-19 pandemic has spread to over 220 countries and territories around the world as of July 2021.
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen AmericanPharmaceuticalReview
February 15, 2022
Legend Biotech Corporation has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel)...
Mersana, Janssen Biotech partner to discover new ADC product candidates pharmaceutical-business-review
February 04, 2022
Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research...
Lawsuit filed against J&J and Janssen for eye damage caused by Elmiron drug Pharmaceutical-Technology
January 28, 2022
Clinical trials started in 2018 recorded a link between Elmiron’s key ingredients and pigmentary maculopathy.
Netherlands approves Novavax Covid vaccine; Won't use Janssen boosters FirstWordPharma
December 27, 2021
The Netherlands has approved the use of Novavax's protein-based COVID-19 vaccine Nuvaxovid, reported NL Times.
NOVA Expands JINKO Platform Pact with Janssen contractpharma
December 16, 2021
Implements its JINKO clinical trial simulation platform for the development of lung cancer models.
MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory pharmatimes
August 12, 2021
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Ponvory (ponesimod) for the treatment relapsing multiple sclerosis (RMS).
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research contractpharma
August 05, 2021
New research groups, PTA and TMI, aim to combat chronic inflammatory diseases and develop oral delivery of macromolar therapeutics.
BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Collaboration with Janssen b3cnewswire
August 03, 2021
German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen's UPTRAVI IV FDA-Approved for PAH contractpharma
August 02, 2021
New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.